>> HELLO.
AND WELCOME TO THE 276th
MEETING OF THE NATIONAL ADVISORY
MENTAL HEALTH COUNCIL.
I'M ELIZABETH, EXECUTIVE
SECRETARY FOR THE COUNCIL AND
ACTING DIRECTOR FOR THE NATIONAL
THE SUITATEITUTE OF MENTAL
HEALTH.
BEFORE WE MOVE ON TO THE
DIRECTOR'S UPDATE, I WANT TO
REMIND YOU OF A FEW ITEMS.
THIS OPEN SESSION IS BEING
BROADCAST TO THE NIH COMMUNITY
AND THE VIEWING PUBLIC.
ALLOWING PEOPLE TO WATCH AND
LISTEN REMOTELY.
THE VIDEO IS ALSO BEING
RECORDING TO ALLOW VIEWING
ON-DEMAND AT A LATER DATE.
COUNCILMEMBERS, THANK YOU FOR
TURNING ON YOUR CAMERAS, I
ENCOURAGE YOU TO KEEP YOUR VIDEO
ON THROUGHOUT THE MEETING.
NIMH STAFF WITH A PRESENTATION
ROLE, WE ASK THAT YOU TURN YOUR
VIDEO ON DURING YOUR
PRESENTATION.
IF YOU JOINED THIS MEETING VIA
MS TEAMS, PLEASE MAKE SURE
YOU'RE MUTED WHEN YOU'RE NOT
SPEAKING.
IT IS NOW MY PLEASURE TO
INTRODUCE THE ACTING DIRECTOR OF
THE NIMH, DR. ANDREA
BECKEL-MITCHENER.
ANDREA HAS SERVED AS THE ACTING
DIRECTOR SINCE APRIL OF THIS
YEAR.
PREVIOUSLY, ANDREA SERVED AND
CONTINUES IN OUR ROLE AS THE
DEPUTY DIRECTOR OF THE BRAIN
RESEARCH THROUGH ADVANCING
INNOVATIVE NEUROTECHNOLOGY OR
THE BRAIN INITIATIVE SINCE 2021.
HER EXPERIENCE ALSO INCLUDES
DIRECTOR POSITIONS AT THE NIMH
IN THE IN THE DISPARITIES
RESEARCH OFFICE, THE OFFICE OF
RURAL MENTAL HEALTH RESEARCH,
AND AS CHIEF OF THE FUNCTIONAL
NEUROGENOMICS PROGRAM AND THE
DIVISION OF NEUROSCIENCE AND
BASIC BEHAVIORAL SCIENCE.
IN ADDITION TO SERVING AS ACTING
PREVISIONER -- DIRECTOR OF THE
NIMH, SHE SERVES ON THE COUNCIL.
I WILL NOW TURN THE MEETING OVER
TO ANDREA.
>> DR. ANDREA BECKEL-MITCHENER:
THANK YOU, LIZ, FIRST I WANT TO
THANK OUR ADVISORY COUNSELOR
MEMBERS FOR THEIR CONTRIBUTIONS
AND THE WORK THEY HAVE DONE TO
PREPARE FOR TODAY.
I ALSO THANK YOU FOR MAKING TIME
TODAY.
AND FOR PARTICIPATING IN THE
COUNCIL MEETING ITSELF.
AS A REMINDER OUR COUNCIL
MEETING IS A TIME FOR
INFORMATION EXCHANGE BETWEEN
INSTITUTE STAFF AND
COUNCILMEMBERS.
AS WELL AS AN OPPORTUNITY FOR
THE COUNCIL TO ADVISE THE NIMH
ON SCIENTIFIC CONCEPTS AROUND
POTENTIAL RESEARCH INITIATIVES
AS WELL AS INSTITUTE POLICY AND
RESEARCH PRIORITIES.
NEXT I WANT TO ACKNOWLEDGE THE
COUNCIL MEMBERS WERE PROVIDED
WITH A SUSPECT 2024 -- SEPTEMBES
THROUGH ELECT ABOUTIC AND VOTED
IN APPROVAL BEFORE TODAY'S
MEETING.
NOW, I'M GOING TO TRANSITION TO
THE NIMH DIRECTOR'S REPORT.
I BELIEVE YOU CAN SEE MY SLIDES.
WHICH IS A LITTLE BIT JITTERY.
I'M GOING TO TURN MY CAMERA OFF
JUST FOR NOW.
IF THAT HELPS.
SO, AS YOU'RE AWARE,
OH, THAT IS
LATER, I APOLOGIZE.
LET ME GET MY SHEET -- MY CHEAT
SHEET.
SO AS LIZ WELL, WELCOME TO THE
276th MEETING OF THE NATIONAL
ADVISORY MENTAL HEALTH COUNCIL.
LIKE ALL OF THE INSTITUTES AT
THE NIMH, THERE IS SIGNIFICANT
CHANGES IN THE LAST FEW MONTHS.
TODAY I'M GOING TO SHARE
IMPORTANT UPDATES ACROSS HHS,
NIMH AND THAT ARE RELEVANT TO
THE MENTAL HEALTH RESEARCH
COMMUNITY.
NOW, DURING, DUE TO ONGOING
LITIGATION, SURROUNDING VARIOUS
ACTIONS AT NIH OR HHS AND NIH,
WE ARE NOT ABLE TO COMMENT ON A
VARIETY OF TOPICS TODAY.
YOU MAY HERE US SAY THAT AND
AWAIT S ACQUAINTANCE ON HHS ON
MANY OF THE ORGANIZATIONAL AND
GRANT RELATED ITEMS YOU MAY HAVE
QUESTIONS ABOUT.
WE WILL DO OUR BEST TO ANSWER
YOUR QUESTIONS OR TAKE THEM BACK
FOR CONSULTATION AND RESPONSE
ONCE WE HAVE IMPORTANT
INFORMATION TO CHAIR SHARE.
SO, I THINK I CLICK FORWARD.
SO, LIZ MENTIONED I STARTED THIS
ROLE IN APRIL AS ACTING DIRECTOR
OF NIMH.
I WANTED TO SAY DEEPLY GRATEFUL
TO DR. SHELLY WHO SERVED AS
ACTING NIMH DIRECTOR SINCE JUNE
OF LAST YEAR.
AND PRIOR TO THAT FOR MANY YEARS
AS NIMH DEPUTY DIRECTOR.
DOCTORS -- HAVE ASKED DOCTOR TO
CONTINUECONTINUE TO SERVE IN HES
ACTING DEPUTY DIRECTOR TO
SUPPORT NIMH AT THIS TIME OF
CHANGE.
BOTH DOCTOR AND I BRING STRONG
INSTITUTIONAL KNOWLEDGE AND
EXPERIENCE LEADING HIGH-PROFILE
NIMH AND NIH O EFFORTS AND ARE
COMMITTING TO SERVING THE NIMH
ESPECIALLY DURING SIGNIFICANT
CHANGE AT NIH AND HHS.
SO YOU KNOW, NIMH IS PLANNING TO
RESUME RECRUITMENT FOR A NEW
NIMH DIRECTOR.
TO NOTE NIMH IS NOT RESPONSIBLE
FOR CONDUCTING THE SEARCH
ITSELF.
AND NIH LEVEL COMMITTEE HANDLES
THOSE PROCESSES AND IS, AS IT IS
THE PRACTICE FOR ALL OPEN
INSTITUTE DIRECTOR POSITIONS,
BUT PLEASE STAY TUNED FOR MORE
INFORMATION ON THAT.
SO, HERE'S OUR AGENDA FOR TODAY.
I'M GOING TO START OFF WITH HHS
AND SOME HHS AND NIH LEADERSHIP
CHANGES AND THEN GO ONTO T TO TE
SUBSEQUENT ITEMS LATER.
OH, SOMETHING, I GUESS I HAVE TO
HAVE MY MOUSE ON THE RIGHT SIDE
OF THE SCREEN.
SO, IN, ON FEBRUARY 13th,
ROBERT F KENNEDY JUNIOR WAS
SWORN IN AS HHS SECRETARY.
AS SECRETARY, MR. KENNEDY
ADMINISTRATORS AND OVERSEES ALL
HHS PROGRAMS, OPERATING
DIVISIONS AND ABOUTS AND ON JUST
RECENTLY ON JUNE 9th, JAMES
O'NEILL WAS SWORN IN AS HHS
DEPUTY SECRETARY.
ON MARCH 25th, DR. J WAS
CONFIRMED AS THE 18th DIRECTOR
OF NIH.
HE REPLACED DOCTOR MONICA WHO
SERVED AS NIH DIRECTOR SINCE
#2023 THROUGH JANUARY OF THIS
YEAR.
THANKS TO DOCTOR WHO SERVED AS
THE ACTOR NIH DIRECTOR FROM
JANUARY 22nd UNTIL THE
DOCTOR'S CONFIRMATION, AND
DOCTOR EMILY REMAINS IN A
POSITION OF PRINCIPLE DEPUTY
UNDER DOCTOR.
DOCTOR IS A PHYSICIAN.
RESEARCHERS, AND HEALTH
ECONOMIST AND HELD A TENURED
PROFESSORSHIP AT STANFORD
UNIVERSITY, JUNE OF MEDICINE.
HE PLACED AN INSTRUMENTAL ROLE
OF SHAMING NIH -- HE WILL PLAY A
INSTRUMENTAL ROLE IN PLACING NIH
ACTIVITIES AND VISION AND MAKE
SURE THAT THEY ALIGN WITH
ADMINISTER'S PRIORITIES.
DOCTOR HAS ELUCIDATED SOME OF
HIS KEY, FIVE KEY PRIORITY AREAS
HE WOULD LIKE TO FOCUS ON.
FIRST HE WANTS NIH TO IMPROVE
POPULATION HEALTH BY PREVENTING,
TREATING AND CURING CHRONIC
DISEASES.
HE ALSO WANTS NIH TO ENSURE
RELIABLE RESULTS BY FOCUS ON
REPRODUCIBILITY AND SCIENTIFIC
RIGOR.
AND THIRDLY, HE WANTS NIH TO
INVEST IN INNOVATION AND EMBRACE
NEW IDEAS TECHNOLOGY, AND
APPROACHES.
DOCTOR IS LOOKING TO STRENGTHEN
PUBLIC TRUST BY IMPROVING
OVERSIGHT AND MAINTAIN SAFETY
AND TRANSPARENCY ESPECIALLY WITH
FOREIGN COLLABORATIONS.
AND FINALLY, HE WANTS TO
ENCOURAGE ACADEMIC FREEDOM
FOSTERING A CUSTOMER THERE IS
OPEN ACADEMIC DISCUSSIONS.
HE ALREADY PROPOSED SOME CHANGES
IN THE INTERMURAL RESEARCH
PROGRAM.
SO WE HOPE TO INVITE DOCTOR TO A
FUTURE COUNCIL MEETING.
HE HAS BEEN DOING THE ROUNDS AT
OTHER COUNCILS.
THAT WAY YOU WILL BE ABLE TO
HEAR DIRECTLY FROM THEM ON THESE
PRIORITIES AND ORD OTHERS.
WHOOPS.
SORRY.
I SEEM TO BE CLICKING ON THE
WRONG -- WRONG AREAS.
HOPEFULLY, DID THE SLIDE CHANGE
TO NEW ACTING DIRECTORS?
I THINK IT MUST HAVE.
>> YES.
WE'RE GOOD.
>> DR. ANDREA BECKEL-MITCHENER:
OKAY.
THANKS.
THERE SEEMS TO BE A DELAY O ON Y
SIDE.
SO MANY MORE CHANGES AT NIH.
THERE ARE SEVERAL INSTITUTES AND
CENTERS WITH NEW ACTING
DIRECTORS.
FIVE OF THEM ARE HERE.
SO THAT MAKES SIX INCLUDING
MYSELF.
W[LISTING DIRECTORS]YOU KNOW, NS
UNDERLINED THERE.
SO MANY OF, ALL OF THESE
INDIVIDUALS ACTUALLY BRING LOTS
OF NIH EXPERIENCE TO THEIR
ROLES.
SO NEXT I'LL PROVIDE AN UPDATE
ON APPROPRIATIONS AND BUDGET ON
MARCH 15th, FOR TRUMP SIGNED
THE FULL YEAR CONTINUING
APPROPRIATIONS AND EXTENSION ACT
OF 2025.
THE FULL YEAR CR CONTINUING
RESOLUTION PROVIDES
$45.5 BILLION TO NIH INCLUDING
$322 BILLION TO NATIONAL
ADVISORY MENTAL HEALTH COUNCIL.
DIRECT APPROPRIATION IS
CONSISTENT WITH OUR FY24 FUNDING
LEVELS.
THERE WAS A, A PREDICTED KNOWN
REDUCTION IN OUR CURES
APPROPRIATION DOWN TO
$40.5 MILLION THIS YEAR.
SOMETHING WE ALREADY KNEW ABOUT.
ON MAY 2nd, THE WHITE HOUSE
RELEASED THE PRESIDENT'S, FY26
BUDGET WHICH REQUESTS
$94.7 BILLION IN DISCRETIONARY
BUDGET AUTHORITY FOR HHS.
THAT IS A 20% REDUCTION FROM '2.
THE FY26 PRESIDENT BUDGET
PROPELLEDS 26 BILLION FOR
RESEARCH, THAT'S A REDUCTION OF
18 BILLION, 39%, THE BUDGET
AUTHORITY COMPARED TO OUR
'25 LEVELS.
IT IS IMPORTANT TO NOTE, THIS IS
A PROPOSAL AND CONGRESS WILL SET
THE BUDGET WITH ANECTED
LEGISLATION, WE LOOK FORWARD TO
SEEING WHAT NUMBERS THEY COME UP
WITH.
ON MAY 14th, OF THIS YEAR, IN
MAY 25th, I THINK, YES, MAY
20th, SORRY, SECRETARY KENNEDY
TESTIFIED BEFORE THE HOUSE
APPROPRIATIONS COMMITTEE, THE
SENATE HEALTH EDUCATION AND
LABOR PASSIONS COMMITTEE AND THE
SENATE APPROPRIATES LABOR HEALTH
AND HUMAN SERVICES, EDUCATED
RELATED AGENCY SUBCOMMITTEE ON
THE PRESIDENT'S FY26 BUDGET.
AND THEN, AGAIN, JUST RECENTLY
ON JUNE 10th, DOCTOR TESTIFIED
BEFORE THAT?
APPROPRIATIONS THE LHHS
SUBCOMMITTEE ON THE FY26 BUDGET
JUSTIFICATION.
SO, HERE'S A LITTLE BIT MORE
INFORMATION ON NIMH FUNDING.
WE SHOW THESE NUMBERS EVERY
YEAR.
IN FISCAL YEAR 24 NIMH FUNDED
600 NEW AND COMPETING RESEARCH
GRANTS WITH A SUCCESS RATE OF
21%.
THE SUCCESS RATE IS DEFINED AS
THE NUMBER OF APLOCATED FUNDED
DIVIDED BY THE NUMBER OF
APPLICATIONS RECEIVED.
YOU THOUGHT THROUGH 2024, WE
HAVE BEEN, WE HAVE BEEN
APPROXIMATELY LEVEL.
AND ALSO QUITE CONSISTENT WITH
OUR SUCCESS RATES.
THIS FIGURE SHOWS NIMH BUDGET
FOR FY25 AND AS IT RELATES TO
THE PREVIOUS NINE YEARS OF
APPROPRIATED CURRENT VERSUS
CONSTANT DOLLARS.
SO THE DARKER BLUE BAND IS
APPROPRIATION IN FY, SORRY, 2016
BUDGET DOLLARS, THE LIGHTER BLUE
BAND SHOWS THE DIRECT
APPROPRIATION AND WHAT YOU'LL
NOTE HERE IS THAT WHILE OVER THE
PAST DECADE OR SO, ACTUAL
PURCHASING POWER REMAINED FAIRLY
CONSTANT UNTIL WE SAW A DROP IN
2024 AND THIS IS THE DROP YOU'LL
SEE IN THE DARK BLUE BAND AND
WHAT LOOKS LIKE ANOTHER DROP IN
2025.
THESE NUMBERS ARE ADJUSTED FOR
INFLATION.
SO WE KNOW OUR INFLATION RATE
WAS HIGHER THAN IT HAD BEEN OVER
THE LAST FEW YEARS.
SO, REALLY WHAT YOU'RE SAYING
HERE IS THAT OUR PURCHASING
POWER HAS DROPPED AND WE
ANTICIPATE THAT AGAIN FOR 2025.
WE'LL MOVE TO A FEW HHS UPDATES.
ON OCTOBER 16th OF LAST YEAR,
HHS ADOPTED A NEW SCIENTIFIC
INTEGRITY POLICY TO ENSURE THE
INTEGRITY OF ALL ASPECTS OF HHS
SCIENTIFIC ACTIVITIES INCLUDING
PROPOSING, CONDUCTING,
REVIEWING, MANAGING, AND
COMMUNICATING ABOUT THE SCIENCE
AND SCIENTIFIC ACTIVITIES.
AND USING THE RESULTS AND
SCIENCE TO INFORM POLICY AND
DECISIONMAKING.
THEN ON FEBRUARY 13th, UNDER
THIS ADMINISTRATION, PRESIDENT
TRUMP SIGNED AN EXECUTIVE ORDER
TO ESTABLISH THE MAKE AMERICA
HEALTHY AGAIN COMMISSION.
THIS IS CHAIRED BY SECRETARY
KENNEDY.
THE COMMISSION IS TASKED WITH
INVESTIGATING AND ADDRESSING THE
ROOT CAUSES OF AMERICA'S
ESCALATING HEALTH CRISIS WITH AN
INITIAL FOCUS ON CHILDHOOD
CHRONIC DISEASES.
THE STRATEGY IS DETAILED IN THE
REPORT WHICH WAS RELEASED ON MAE
ACCESSED ONLINE.
A FEW NIH UPDATES FOR YOU.
WE RECENTLY BUILDING ONE, NIH
CENTRAL, AS WE CALL IT, RECENTLY
INITIATED A FEW NEW PROGRAMS ON
APRIL 29th, NIH ANNOUNCING THE
INTENT TO ESTABLISH A NEW
OFFICE, THE OFFICE OF RESEARCH,
INNOVATION, VALIDATION, AND
APPLICATION, WITHIN THE NIH
OFFICE OF THE DIRECTOR.
THIS NEW OFFICE WILL COORDINATE
NIH WIDE EFFORTS TO DEVELOP AND
VAL AND SCALE THE USE OF
NONANIMAL APPROACHES ACROSS THE
AGENCY AND SURF AS A HUB FOR
INTERAGENCY COORDINATION AND
REGULATORY TRANSLATION FOR
PUBLIC HEALTH PROTECTION.
ANOTHER UPDATE FOR YOU ALL
RELEVANT FOR THIS COMMUNITY, FOR
OUOUR COMMUNITY ON MAY 27th, NIH
SHARED A NEW RESEARCH
OPPORTUNITY FOR AUTISM, CALLED
THE AUTISM DATA SCIENCE
INITIATIVE.
ADSI.
THIS INITIATIVE, WHICH IS BEING
LED BY NIH OD, SEEKS TO BRING
TOGETHER DIVERSE DATA RESOURCES
TO EXPLORE POSSIBLE
CONTRIBUTIONS TO THE CAUSES OF
AUTISM.
THE TIMELINE FOR THIS IS QUITE
COMPRESSED.
SINCE AWARDS NEED TO BE MADE
THIS FISCAL YEAR.
IT USES THE FUNDING AUTHORITY
WITH AN ACCELERATED PROCESS.
SO IMPORTANTLY, RESEARCH
APPLICATIONS ARE DUE JUNE 2
JUNE 27th.
THERE HAVE BEEN NUMEROUS NIH
POLICY UPDATES RELATED THE
GRANTS.
WE ENCOURAGE YOU TO PLEASE CHECK
AND REGULARLY REVIEW THE FULLEST
OF NOTICES OF NIH POLICY CHANGES
TO STAY UP-TO-DATE ON WHAT NEW
POLICIES AND GUIDANCE ARE
AVAILABLE.
WHO REHIGHLIGHTING A FEW HERE,
THIS IS BY NO MEANS EXHAUSTIVE.
SO THE NIIMPLEMENTED SEVERAL
CHANGES FOR GRANT APPLICATIONS
WITH DUE DATES ON OR
AFTERJANUARY 25th OF THIS
YEAR.
INCLUDING SIMPLIFIED REVIEW
FRAMEWORK, YOU MAY HAVE HEARD OF
THIS, FOR PEER RER VIEW OF GRANT
APPLICATIONS AND REVISIONS TO
INSTRUCTIONS AND REVIEW CRITERIA
FOR FELLOWSHIP APPLICATIONS AND
INSTITUTIONAL TRAINING GRANTS.
NIH, THE ADOPTION OF THE COMMON
FORM BIOGRAPHICAL SKETCH, AND A
NEW BIOGRAPHICAL SKETCH
SUPPLEMENT ORIGINALLY SCHEDULED
FOR MAY OF THIS YEAR IS
POSTPONED.
PLEASE CONTINUE TO USE THE NIH
SPECIFIC FORMAT PAGES CURRENTLY
AVAILABLE UNTIL FURTHER NOTICE.
AND FINALLY IN DECEMBER OF 2024,
NIH PUBLISHED AN UPDATED PUBLIC
ACCESS POLICY.
WE REMOVING THE EMBARGO PERIODS
SO RESEARCHERS, STUDENTS AND
MEMBERS OF THE PUBLIC HAVE RAPID
ACCESS TO RESEARCH FINDINGS.
THE ORIGINAL IMPLEMENTATION DATE
WAS THE END OUT THIS CALENDAR
YEAR.
THAT HAS BEEN MOVED UP TO
JULY 1st, 2025.
THAT'S RAPIDLY UPCOMING.
THIS IS A PLANNED PROCESS.
THEY JUST MOVED IT UP BY SIX
MONTHS.
SO NEXT I WILL MOVE TO A FEW --
OKAY.
NIMH NEWS.
AND TO KNOW.
SO, FIRST OF ALL, THIS NEXT FEW
SLIDES ARE REQUIRED TO BE
PRESENTED TO COUNSEL EVERY THREE
YEARS.
THE NIMH REVITALIZATION AC ACT F
1993, THAT THERE MUST BE A
REPORT ON A TRIENNIAL BASIS HOW
THE INSTITUTE COMPLIE COMPLIED H
REQUIREMENTS WITH WOMEN AND
RESEARCH.
SO THERE ARE SIMILAR STANDARDS
FOR MAINTAINING, COLLECTING DATA
ON RACE AND ETHNICITY.
THE GOALS OF THE POLICY ARE TO
ENSURE THAT WOMEN AND MINORITIES
ARE INCLUDED IN NIH FUNDED
RESEARCH.
AND NIH PHASE III CLINICAL
TRIALS ARE DEFINED IN A MANNER
TO EXAMINE DIFFERENTIAL EFFECTS
OF INTERVENTION ON MEN AND
WOMEN, AND RACI RACIAL AND ETHNC
MINORITY GROUPS.
SO A SPECIAL THANKS TO OUR
OFFICE OF CLINICAL RESEARCH.
NIH FUNDED OUR DATA ON OUR
FUNDED AND EXTRA MURAL CLINICAL
RESEARCH AND NIH PHASE III
CLINICAL TRIALS.
SO COUNCILMEMBERVISE RECEIVED
THIS REPORT AND VOTED ON ITS
APPROVAL.
WE THANK YOU FOR THAT.
BUT TO BE IN COMPLIANCE THE NEXT
FEW SLIDES I WILL JUST PROVIDE
AN OVERVIEW OF FEW OF THE KEY
FINDINGS.
THE SLIDES SHOW THE SEX OF
PARTICIPANTS ON THE LEFT IS
EXTRA MURAL CLINICAL RESEARCH.
ON THE RIGHT IS OUR INTERMURAL
PROGRAM.
AS INDICATED BY THE N, THE
NUMBER OF SHOWN ON THE X AXIS
THERE WAS AN INCREASED IN
PARTICIPANT ENROLLMENT, WITH
EXTRA MURAL STUDIES.
NOTE THE VERY LARGE INCREASE IN
IN RORAL CAN MOSTLY BE
ATTRIBUTED TO A DENTIN MENTAL
HEALTH STUDY THAT ENROLLED
2.6 MILLION PARTICIPANTS AND
MANY OF THE PARTICIPANTS NOT
REPORTING THEIR SEX.
YOU WILL SEE A VERY LARGE
INCREASE IN UNKNOWN/NOT
REPORTED.
AND THREN THERE WAS A STARK
DECREASE IN THE PERCENTAGE OF
MEN ENROLLED.
ACROSS ALL FISCAL YEARS
ENROLLMENT PERCENTAGES OF WOMEN
REMAINED CONSISTENT.
BUT LOOKING AT THE INTERMURAL
CLINICAL RESEARCH PROGRAM, THE
PERCENTAGES FOR ALL CATEGORIES
REMAINED CONSISTENT ACROSS THE
THREE FISCAL YEARS.
THIS SLIDE DISPLAYS THE RACE OF
PARTICIPANTS.
IT IS A VERY SIMILAR PROFILE.
EXTRA MURAL RESEARCH, AGAIN, A
SIGNIFICANT RESEARCH IN THE
UNKNOWN AND NOT REPORTED DUE TO
THE LARGE EXTRA MURAL PROJECT I
JUST MENTIONED.
AGAIN -- THIS IS -- ALL
CONSISTENT WITH -- WE ARE IN
COMPLIANCE AND CONSISTENT WITH
THE NUMBERS THAT WE COULD EXPECT
TO SEE.
MOST PARTICIPANTS IDENTIFIED AS
WHITE.
FOR THE INTERMURAL PROGRAM, 67%
OR SO AND OUR LARGEST AND RACIAL
ETHNIC MINORITY GROUP WERE BLACK
OR AMERICAN PARTICIPANTS,
AVERAGING ABOUT 11%.
THAT FULFILLS OUR DUTY.
A FEW OTHER STAFF UPDATES.
AGAIN, YOU HAVE SEEN HOW MANY
POSITIONS WE HAVE THAT ARE
ACTING.
I WANT TO ACKNOWLEDGE FEW
LEADERSHIP CHANGES HERE AT NIMH.
YOU MET DOCTOR LIZ WHO IS NOW
THE ACTING DIRECTOR OF THE DEA.
THE DIVISION OF EXTRA MURAL
ACTIVITIES.
I ALSO WANT TO NOTE THAT DOCTOR
WAS APPOINTED ACTING DIRECTOR OF
THE NATIONAL ADVISORY MENTAL
HEALTH COUNCIL'S DIVISION OF
TRANSLATIONAL RESEARCH.
DR. RUBEN IS SERVING AS ACTING
DIRECTOR OF THE DIVISION OF DATA
SCIENCE AND TECHNOLOGY.
AND DR. KRISTINA WAS APPOINTED
AS ACTING DIRECTOR FOR NIMH'S
DIVISION OF SERVICES AND
INTERVENTION RESEARCH UPON THE
DEPARTURE OF PAT.
AND I'M NOTING THE TIME, I'M
PROBABLY GOING TO HAVE TO SPEED
UP A LITTLE BIT, BUT I'M NOT
GOING TO SPEED THROUGH THIS
SLIDE BECAUSE IT IS IMPORTANT TO
NOTE AND CELEBRATE OUR NIMH
STAFF ACCOMPLISHMENTS.
WE HAVE A NUMBER OF NIMHERS, WE
ARE VERY PROUD THEY HAVE BEEN
RECOGNIZED FOR THEIR EFFORTS.
[LISTING EFFORTS]
SO, I -- I THINK WHAT I'M GOING
TO DO, WE HAD A NUMBER OF
SCIENCE SLIDES THAT WE WANTED TO
HIGHLIGHT.
UNFORTUNATELY, SINCE WE HAD TWO
COUNCIL ROUNDS WE HAVE A VERY
COMPRESSED CYCLE, I THINK I'M
GOING TO TALK ABOUTING
DIRECTOR'S PREROGATIVE AND
NOT -- PRESENT THIS AMAZING
SCIENCE.
SO WE LEAVE ENOUGH TIME FOR
QUESTIONS AND COMMENTS FROM
COUNCIL.
SO, WITH THAT, I WILL CLOSE THE
DIRECTOR'S UPDATE.
AND OPEN FOR QUESTIONS.
SO I BELIEVE -- AM I STILL
SHARING?
>> NO, YOU'RE GOOD, ANDREA.
>> DR. ANDREA BECKEL-MITCHENER:
OKAY.
ALL I CAN SEE IS -- OH, OKAY.
HERE WE ARE.
APOLOGIES.
OKAY!
ANY QUESTIONS ON COMMENTS FROM
COUNCIL?
LIZ, CAN I ASK YOU TO CALL ON
FOLKS?
>> YES.
>> THANK YOU, DR. ANDREA
BECKEL-MITCHENER FOR THAT
PRESENTATION.
I WAS CURIOUS ABOUT WHERE YOU
COULD SHARE ANYTHING ABOUT WHAT
THE STRATEGY MIGHT LOOK LIKE FOR
FY26 GIVEN THE POTENTIAL BUDGET
DECREASES.
I UNDERSTAND WE DON'T KNOW WHAT
THAT WOULD LOOK LIKE.
BUT I LOVE TO HEAR A LITTLE BIT
ABOUT WHAT YOU ALL ARE THINKING
WITH REGARD HOW TO MANAGE
POTENTIAL CUTS OF THE SCOPE THAT
HAVE BEEN DESCRIBED.
>> DR. ANDREA BECKEL-MITCHENER:
YES.
SO WE HAVE TO MODEL OUR BUDGET
FOR ALL POTENTIAL OUTCOMES
INCLUDING WHAT MIGHT BE THIS
LARGE CUT.
SO WE'RE DOING THAT.
AND ACTUALLY, THIS WAS RELEASED
AS PART OF THE PRESIDENT'S
BUDGET AS WELL.
WE HAVE A FEW TRICKS UP OUR
SLEEVE THAT WE CAN USE THAT
ALLOWS US TO SPEND MORE MONEY
THIS YEAR AND THAT WOULD RESERVE
MONEY FOR NEXT YEAR.
WE ARE UNSURE HOW MUCH WE'RE
GOING TO BE ABLE TO USE THOSE
TOOLS AND HOW MANY, YOU KNOW, TO
GET THE GRANT DOLLARS OUT THE
DOOR FOR THIS YEAR.
EVERYTHING WE SPEND THIS YEAR
IMPACTS OUR SPENDING FOR NEXT
YEAR.
SO, I DON'T HAVE SPECIFICS FOR
YOU.
BUT WE ARE MODELING FOR THE
POTENTIAL OUTCOME.
AGAIN, THAT'S JUST A PROPOSAL.
AND WE'RE LOOKING FORWARD TO
SEEING WHAT CONGRESS COMES UP
WITH AND HOPEFULLY, YOU KNOW, WE
WILL WORK WITH WITHOUT EVER
CONGRESS GIVES US, OF COURSE.
BUT WE DON'T HAVE ANY SPECIFIC
STRATEGIES.
YOU KNOW, AS MYSELF AND MY
COLLEAGUES AND ACTING POSITIONS,
WE ARE -- COMMITTED TO FUNDING
THE AREAS, THE PRIORITY AREAS
THAT HAVE ALREADY BEEN
IDENTIFIED.
PART OF OUR STRUT ARE STRATEGIC
PLAN, THE ADVISE OF COUNCIL OVER
THE LAST SEVERAL YEARS.
SO THOSE WILL REMAIN OUR
PRIORITY AREAS.
WE ARE NOT ANTICIPATING CHANGES
DIRECTION IN ANY SIGNIFICANT WAY
AND AWAIT A NEW DIRECTOR FOR
THAT POSSIBILITY.
>> DR. MURRAY?
>> THANK YOU FOR THAT VERY
THOROUGH REPORT.
I'M ALSO WONDERING WHEN OR NOT
STUD SECTION MEMBERS HAVE BEEN
TRAINED SPECIFICALLY FOR THE NEW
SIMPLIFIED FRAMEWORK?
TRAINING ON GOING FOR THAT?
>> DR. ANDREA BECKEL-MITCHENER:
I -- SO, I'M AWARE THROUGH THE
GRAPEVINE THAT YES, THEY HAVE
BEEN GIVEN DIRECTION FROM CSR
AND EVERYBODY HAS BEEN MADE
FULLY AWARE O OF THAT.
I PERSONALLY DON'T KNOW THE
EXTENT OF THAT TRAINING, IF LIZ,
YOU HAVE MORE INFORMATION ON
THAT?
>> YEAH.
THEY HAVE BEEN TRAINED.
AND ON THE CSR AND THE OFFICE OF
EXTRA MURAL RESEARCH WEB PAGE,
THE TRAINING SLIDES POSTED.
SO THAT THE EXTRA MURAL
COMMUNITY CAN SEE HOW THAT
TRAINING OCCURRED.
OR WHAT WAS INCLUDED IN THE
TRAINING.
OKAY.
YES?
>> YES.
THANK YOU VERY MUCH.
AND THANK YOU FOR THAT
PRESENTATION.
THE -- THERE ARE -- A COUPLE
QUESTIONS.
ONE OF THE THINGS THAT YOU --
ALLUDED TO BRIEFLY WAS THE
SEARCH FOR A PERTINENT DIRECTOR
AND SAID THAT IS NOT IN THE
HANDS OF NIMH, BUT ANY
INFORMATION THAT YOU MAY HAVE IN
TERMS OF TIMELINES AND IN TERMS
OF HOW THAT COMMITTEE IS MOVING
FORWARD WOULD, I THINK, BE
HELPFUL TO THIS GROUP.
THE OTHER MAJOR ISSUE THAT CAME
UP THIS SPRING IS AROUND
INDIRECT COST RECOVERY AND I, I
DON'T WANT TO SAY, YOU KNOW,
LEAD THE QUESTION, BUT -- I
THINK THAT -- THE -- BROADER
COMMUNITY IS INTERESTED IN HOW
THOSE DISCUSSIONS ARE CONTINUING
AND -- AND -- WHAT -- WHAT
SCOPE FOR -- FOR MOVING FORWARD
NIMH IS FINDING -- WITHIN YOUR
VARIOUS CONSTRAINTS.
>> DR. ANDREA BECKEL-MITCHENER:
SO I WILL ANSWER THE SECOND PART
FIRST.
INDIRECT COST RATE IS ONE OF THE
ITEM WE CAN NOT COMMENT ON.
THERE IS PENDING LITIGATION ON
THAT.
SO WE DON'T HAVE ANY INFORMATION
OTHER THAN WHAT YOU'RE READING
IN THE NEWS.
IN TERMS OF THE DIRECTOR'S
SEARCH, YOU MAY RECALL THIS WAS
AN OPEN SEARCH LAST YEAR.
IT, THERE WAS A SEARCH COMMITTEE
CONVENED FOR IT.
THAT SEARCH WAS PUT ON PAUSE.
AND W WE HAVE UNOFFICIAL
ASSURANCES THAT WE HAVE, I
GUESS, WE COULD CALL THEM MOSTLY
ALSO ASSURANCES THAT THEY ARE
AWARE OF THE VACS AGENCY,
OFFICIALLY LEFT BY JOSH, OF
COURSE, AND -- THIS EXECUTIVE
RECRUITMENT OFFICE AT NIH WE
UNDERSTAND THAT IT IS ONGOING
AND UNDERWAY.
BUT WE DO NOT GET ANY
INFORMATION ON THAT.
IT IS REALLY HANDLED AT THE NIH
LEVEL.
>> YES?
>> YEAH.
THANK YOU.
IN REVIEWING THE MAHA REPORT, I
SAW A STRONG EMPHASIS ON
CHILDREN'S BEHAVIORAL HEALTH.
I WAS CURIOUS TO LEARN MORE
ABOUT HOW NIMH CONSTITUENTS MAY
HAVE BEEN ENGAGED IN THE PROCESS
AND HOW IT MAY INFORM FUTURE
STRATEGY FOR NIMH?
>> DR. ANDREA BECKEL-MITCHENER:
TO MY KNOWLEDGE, THE NIH
RESEARCH COMMUNITY MAYBE HAD
LIMITED CONTACT IF AT ALL ON
GENERATING THE MAHA REPORT.
THE INFORMATION IN THERE.
I WILL SAY, HOWEVER, STAFF AT
THE INSTITUTE ARE VERY
INTERESTED IN GETTING INTO THE
DETAILS.
WE HAVE ALREADY DONE A LITTLE
BIT OF WORK INTERNALLY TO
UNDERSTAND HOW THE DISORDERS
THAT HEALTH CARES MOST ABOUT AND
THE CONDITIONS ARE REFLECTED IN
THAT REPORT AND HOW WE CAN
CONTRIBUTE TO RESEARCH, THE
RESEARCH OPPORTUNITIES AROUND
THE ITEMS THAT WERE IDENTIFIED.
>> AND NOW, WE'RE READY TO MOVE
ONTO THE CONCEPT CLEARANCES.
>> DR. ANDREA BECKEL-MITCHENER:
YOU'RE KEEPING US ON TIME.
[ LAUGHTER ]
OKAY.
THANKS, LIZ.
OKAY.
SO, AS YOU ARE AWARE, COUNCIL
MEETINGS THIS IS ONE OF THE FUN
THINGS, NIMH MAY PRESENT
SCIENTIFIC CONCEPTS FOR COUNSEL
REVIEW.
OUR CONCEPT PRESENTATIONS ARE
INTENTIONALLY GOOD INARE, THE
PURPOSE OF THE CONCEPT
CLEARANCES IS FOR NIMH TO
RECEIVE YOUR EARLY FEEDBACK ON
THE POSSIBLE FUTURE RESEARCH
DIRECTIONS INCLUDING SUGGESTIONS
TO HELP FURTHER SHAPE THE
POTENTIAL INITIATIVES.
SO FOLLOWING MY BRIEF COMMENT, A
BRIEF DESCRIPTION OF EACH
CONCEPT WILL BE MADE AVAILABLE
TO YOU VIA THE ASR.
I THINK IT IS ALREADY PRESENT IN
THERE.
WE HAVE FOUR CONCEPTS TO PRESENT
TODAY.
GIVEN OUR TIME CONSTRAINTS WE
ARE ASKING THAT YOU PLEASE HOLD
QUESTIONS AND COMMENTS UNTIL ALL
FOUR CONCEPTS HAVE BEEN
PRESENTED.
BUT KEEP THEM IN YOUR MIND,
BECAUSE WE WILL RETURN TO YOUR
COMMENTS AND QUESTIONS FOLLOWING
THE FINAL PRESENTATION.
SO FIRST PRESENTATION IS FROM
DR. JOEL SHERYL ON RESEARCH TO
OPTIMIZE THE EFFECTIVENESS AND
DEPLOYAL OF SUICIDE DEPRESSION
SERVICES.
THANK YOU, IT WAY, JOEL.
>> GREAT.
THANK YOU, ANDREA.
GOOD AFTERNOON, EVERYONE.
I APPRECIATE THIS CONCEPT.
ON BEHALF OF JANE, STEVEN, AND
OTHER INSTITUTE COLLEAGUES.
NEXT SLIDE PLEASE.
RESEARCHERS YIELDED
EVIDENCE-BASED PREVENTION
STRATEGIES AND TOOLS FOR
SCREENING, FOR RISK
IDENTIFICATION, AND
STRATIFICATION, AND FOR
INTERVENING TO REDO SUICIDE
RISK.
YET, THE LACK OF SCALABLE
APPROACHES FOR TRAINING,
SUPERVISING AND MONITORING THE
QUALITY OF DELIVERY BY ARE BY
CLINICIANS AND OTHER PROVIDERS
LIMITS ACCESS TO EFFECTIVE
EVIDENCE-BASED SUICIDE
PREVENTION.
AS ILLUSTRATED BY THIS MAP,
COUNTY LEVEL BEHAVIORM HEALTH
PROVIDER SHORTAGES THAT IMPACT
LARGE SEGMENTS OF THE U.S.
POPULATION FURTHER UNDERSCORE
THE NEED FOR A MORE ROBUST
COMPLIMENTERARY AND WELL
STRAINED PROVIDER BASE INCLUDING
SUSTAINABLE STRATEGY FOR
INTEGRATING PEER SUPPORT
SPECIALISTS AND OTHER
PARAPROFESSIONALS INTO CLINICAL
AND COMMUNITY PRACTICE SETTINGS.
NEXT SLIDE PLEASE.
ACCORDINGLY, THE GOAL OF THIS
CONCEPT IS TO ENCOURAGE RESEARCH
THAT IS FOCUSED ON OPTIMIZING
AND TESTING PROVIDING TRAINING
STRATEGIES AND QUALITY
MONITORING TOOLS FOR SUSTAINED
FIDELITY IN DELIVER OF
EVIDENCE-BASED SUICIDE
PREVENTION SERVICES AND
DEVELOPING AND TESTING SCALABLE
AND SUSTAINABLE PEER SUPPORT
THAT COMPLIMENT AND EXTEND
CLINICAL SERVICES AND CLINICAL
AND COMMUNITY SETTINGS.
WITH THIS CONCEPT WE ENCOURAGE
RESEARCH THAT INFORMED BY END
USERS INCLUDING SERVICE USERS,
OTHERS WITH LIVED EXPERIENCES
PROVIDERS AND ADMINISTRATORS WHO
MAKE DECISIONS ABOUT THE
ADOPTION, CREDENTIALING AND
REIMBURSING OF SERVICES AND
EMPHASIZE RESEARCH INFORMED
APPROPRIATES THAT ARE SCALABLE
AND SUSTAINABLE.
NEXT SLIDE PLEASE.
SO, FOR EXAMPLE, RESEARCH ON
PROVIDER TRAINING AND QUALITY
MONITORING APPROPRIATES MIGHT
INVOLVE CLINICAL TRIALS TO
OPTIMIZE AND TEST PROVIDER LEVEL
TRAINING AND SUPERVISION
STRATEGIES TO ACHIEVE INITIAL
COMPETENCY AND SUSTAINED
FIDELITY AND EVIDENCE-BASED
ASSESSMENT AND INTERVENTIONS.
OTHER RESEARCH MIGHT FOCUS ON
DEVELOPING AND PSYCHOMETRICALLY
VALIDATING SCALABLE APPROPRIATES
TO MEASURING, MONITORING AND
PROMOTING SUICIDE PREVENTION
SERVICES AND ACROSS THE RESEARCH
ENCOURAGE USE OF NOVEL
TECHNOLOGIES TO SUPPORT TRAINING
AND REALTIME MONITORING OF
SERVICE DELIVERY AND QUALITY.
ADDITIONAL RESEARCH FOCUSED ON
EXTENDING CLINICIAN SERVICES,
MIGHT ADDRESS PILOT TRIALS WITH
THE FEASIBILITY, ACCEPTABILITY,
SAFETY AND THE EFFECTIVENESS OF
PEER SUPPORT MODELS THAT TEST
CLEAR ROLES FOR PEER SUPPORT
SPECIALISTS ALIGNED WITH THEIR
TRAINING AND UNIQUE SKILL SET
AND UNDERSTANDING FOCUSING ON
UNDERSTANDING TARGETS
EFFECTIVENESS, AND EMPHASIZING
AND ANTICIPATING NEEDED SUPPORT
FOR RISK MANAGEMENT, OUTCOME
MONITORING, TRAINING AND
SUPERVISION AND MODELS THAT
ANTICIPATE CREDENTIALING AND
REIMBURSEMENT SITUATIONS.
AND OTHER HEALTH RECORDS AND
ADMINISTRATIVE DATA TO EVALUATE
INNOVATIVE APPROPRIATES TO FOR
DEPLOYING SUPPORT SERVICES
INCLUDING TELEHEALTH AND
INNOVATIVE REIMBURSEMENT
POLICIES.
THANK YOU FOR YOUR TIME AND
ATTENTION.
>> THANK YOU, JOEL.
WE WILL MOVE RIGHT INTO DOCTOR .
JOVDR.JOVIER EVANS.
>> GOOD AFTERNOON.
I'M PLEASED TO PRESENT THIS
INITIATIVE WHICH WAS PREPARED IN
COLLABORATION WITH MY COLLEAGUES
FROM THE DECISION OF SERVICES
AND THE INTERVENTIONS AND
RESEARCH.
[LISTING COLLEAGUES [.
NEXT SLIDE PLEASE.
ADULTS AGING WITH SMI ARE MORE
LIKELY THEN THOSE WITHOUT MENTAL
ILLNESS TO PRESENT CHALLENGES
THAT IMPACT THEIR PHYSICAL AND
MENTAL HEALTH.
INCLUDING CLINICAL CHANGES,
HEALTH CONDITIONS, RESIDENTIAL
MOBILITY CHANGES, AND FRAGMENT
CHANGES WITH REGARD TO SERVICES
AND SUPPORTS ACROSS HEALTHCARE
SERVICES AND SYSTEMS.
DESPITE THE HIGH RISK OF MEDICAL
COMORBIDITY AND
INSTITUTIONALIZATION, OLDER
ADULTS ARE UNDER TREATED,
HIGHLIGHTING THE NEED FOR
EFFECTIVE INTERVENTIONS THAT
ADDRESS THE MENTAL HEALTH NEEDS
OF THIS PARTICULAR POPULATION.
AND SOME PROGRESS HAS BEEN MADE
IN ESTABLISHING THE
EVIDENCE-BASED IN EFFECTIVE
INTERVENTIONS, THOSE EFFORTS TO
TEND TO BE SPECIFIC TO LATE LIFE
DEPRESSION OR ANXIETY DISORDERS.
AND FEW STUDIES FOC FOCUS ON THE
ADAPTATION AND IMPLANTATION OF
EVIDENCE-BASED PRACTICES FOR
OLDER ADULTS WITH SEVERE MENTAL
ILLNESS.
MANY WHO EXPERIENCE OR AT
HIGH-RISK OF DEVELOPING
COOCCURRING CHRONIC HEALTH
CONDITIONS.
FURTHER THESE INTERVENTIONS AND
SERVICES DON'T SUFFICIENTLY
ADDRESS OTHER VARIABLES ADDRESS
OLDER ADULTS WITH SMI ACCESSES
AND RECEIVE AND RESPOND TO
TREATMENT INCLUDING SOCIAL
SUPPORTS, ISOLATION, PHYSICAL
MORBIDITY, LIMITATIONS AND THEIR
RESIDENTIAL STATUS.
HEALTHCARE SYSTEM STRATEGY FOR
IMPROVING ADOPTION,
IMPLEMENTATION, AND
SUSTAINABILITY OF EVIDENCE-BASED
INTERVENTIONS ARE ALSO LIMITED.
THIS IS UNFORTUNATE GIVEN KNOWN
BARRIERS TO SERVING OLDER ADULTS
LIVING WITH SMI, INCLUDING LACK
OF ACCESS TO SPECIALTY MENTAL
HEALTH PROVIDERS, LACK OF
COORDINATION MOON PSYCHIATRIC
SOCIAL AND AGING SERVICES.
INSUFFICIENT WORKFORCE WITH
GERIATRIC EXPERTIZE AND OTHER
ITEMS FROM GENERAL HEALTHCARE TO
GERIATRIC SERVICES.
NEXT SLIDE PLEASE.
SO, THE GOAL OF THIS PARTICULAR
CONCEPT IS TO TRY TO ADDRESS
THESE GAPS THAT THERE'S A CLEAR
PUBLIC HEALTH NEED WITH REGARD
TO THERAPEUTIC AND SERVICES
RESEARCH.
THAT WILL HELP ADDRESS PRACTICE
RELEVANT ISSUES AND IT CAN
CONDUCTED IN SETTINGS WHERE
OLDER ADULTS WITH SMI ARE MOST
LIKELY TO RECEIVE OR NEED MENTAL
HEALTH CARE.
THUS, THE CONCEPT IS ALIGNED
WITH ASPECTS OF THE TRIENNIALLER
STRATEGIC PLAN FOR RESEARCH
AIMED TO SUPPORT RESEARCH THAT
SUPPORTS THE UP A TUIMATION
EQUATION, EFFECTIVENESS,
IMPLEMENTITATION, AND
SUSTAINABILITY OF EMPIRICALLY
SUPPORTED INTERVENTION INTERVENS
ROUTINE CARE SETTINGS FOR OLDER
ADULTS LIVING WITH SMI.
NEXT SLIDE PLEASE.
HERE ARE CLEAR EXAMPLES OF
RELEVANT RESEARCH THAT WOULD BE
SUPPORTED BY THE INITIATIVES
THAT WOULD INCLUDE, BUT THEY NOT
BE LIMITED TO RESEARCH RELATED
TO ADAPTING, OPTIMIZING, AND
IMPLEMENTING EFFFACING
TREATMENTS AND STRATEGIES TO
IMPROVE BOTH CLINICAL AND
FUNCTIONAL OUTCOMES.
WHICH MAY INCLUDE THE REDUCTION
OF COOCCURRING CHRONIC HEALTH
SYSTEMS AND CONDITIONS AMONG
PEOPLE AGING WITH SMI.
RESEARCH THAT MAY EXAMINE
INNOVATIVE IMPLEMENTATION
STRATEGIES FOR IMPROVING THE
UPTAKE, EFFECTIVENESS, AND
MAINTENANCE OF THE EMPIRICALLY
SUPPORTED INTERVENTION IN
ROUTINE PRACTICE COMMUNITY AND
OTHER SERVICE SETTINGS.
AND FINALLY RESEARCH THAT MAY
FOCUS ON HEALTHCARE SYSTEM LEVEL
FACTORS AND APPROPRIATES FOR
ADDRESSING LATE LIFE SMI AND
IMPROVING ACCESS ORGANIZATION
AND SUSTAINABILITY OF THESE
EVIDENCE-BASED INTERVENTIONS AND
RELEVANT CARE SETTINGS.
THANK YOU FOR YOUR TIME AND
ATTENTION.
>> ANDREA, I THINK YOU'RE ON
MUTE.
>> DR. ANDREA BECKEL-MITCHENER:
THAT IS GOOD.
BECAUSE I MISPRONOUNCED THE
PSYCHOMIMETIC AGENTS.
SO DR. JONATHAN SABBAGH FOR THIS
CONCEPT.
>> HELLO.
AND THANK YOU ALL FOR THE
OPPORTUNITY TO PRESENT THIS
CONCEPT.
I WILL ACCELERATING SOLUTIONS TO
UNDERSTAND THE POTENTIAL
FAST-ACTING AGENTS.
NEXT SLIDE PLEASE.
SO PSYCHOMIMETIC AGENTS, PMAs
ARE SEVERAL CLASSES OF DRUGS,
[LISTING DRUGS].
OVER THE LAST 20 YEARS OR SO,
THERE'S BEEN A VENEWELLED RENEWT
IN LOOKING AT THE DRUGS.
THERE'S ALSO BEEN A GROUNDSWELL
OF INTEREST AND INVESTMENT IN
THESE DRUGS AND RELATE ULMALL
EGGS FROM INDUSTRY.
THE FIGURE TON THE RIGHT IS A
SNAP A LOT OF THE DOZENS OF
COMPANIES THAT ARE PURSUING GIRL
DETHAT ARE PURSUING DRUGDEVELOP.
NEXT SLIDE PLEASE.
HOWEVER, THERE ARE SEVERAL
CHALLENGES ASSOCIATED WITH
PMAs.
THE PREFOUND SUBJECTIVE EFFECTS
THAT TYPICALLY OCCUR FOLLOWING
THE ADMINISTRATION OF THE DRUGS,
AND IT LEADS TO FUNCTIONAL
UNBLINDING IN CLINICAL TRIALS
WHERE IN PARTICIPANTS ARE
ACUTELY AWARE OF IF THEY
RECEIVED ACTIVE DRUG OR PLACEBO.
COUPLED WITH THE LARGEECT
PACTANCY EFFECTS THAT THE
TREATMENT NONSPECIFIC EFFECTS
MAY BE CONTRIBUTING TO POSITIVE
TRIAL RESULTS.
THE CHOICE OF WHICH PLACEBO TO
USE, WHETHER INSERT OR
PSYCHOACTIVE TO MIMIC ASPECTS IS
DEVELOPMENT AND NOT UNIFORM
ACROSS STUDIES.
THE ROLE THAT PSYCHOTHERAPY
PLAYS IN THE BENEFICIAL EFFECTS
OBSERVED IS ALSO AN OPEN
QUESTIONS WITH SOME TRIALS
UTILIZING A STANDARDIZED
APPROACH AND OTHERS WITH MINIMAL
SUPPORT.
PMAs HAVE COMPLEX
PHARMACOLOGY, AS EVIDENCED BY
THE FIGURE ON THE RIGHT, WHICH
DEFECTS RECEPTOR TARGETS FOR LSD
WITH THE RED AND GREEN DOTS.
THIS IS COMPLICATED DRUG
DEVELOPMENT EFFORTS I IT IS NOT
CLEAR WHAT ARE THE EFFECTS OR
MECHANISM OF ACTION ARE
UNDERSTOOD.
THE CHALLENGES ARE NOT UNIQUE TO
PMAs TH THEY ARE EXACERBATED BY
THE INTENSE EFFECTS OF THE DRUGS
IN THE HIGH ENTHUSIASM ON THE
PATIENTS AND CLINICIANS.
NEXT SLIDE PLEASE.
THE OVERALL GOAL OF THIS CONCEPT
IS TO FOSTER RESEARCH THAT AIMS
TO BETTER UNDERSTAND THE
MECHANISMS AND POTENTIAL
THERAPEUTIC IMPACT OF PMAs.
EXAMPLES OF RESEARCH QUESTIONS
THAT COULD BE POSED INCLUDE HOW
CAN TRIAL DESIGNS TO BE
OPTIMIZED TO ADDRESS AND
POTENTIALLY OVERCOME THE
CHALLENGES ASSOCIATED WITH
PMAs.
AND WHAT TRANSLATABLE
PHARMACODYNAMIC BIOMARKERS CAN
BE DEVELOPED FOR A BETTER DRUG
EFFECT.
AND HOW CAN WE BETTER UNDERSTAND
WHERE PSYCHOTHERAPY AND THE
PRONOUNCED EFFECTIVE PLAY A ROLE
IN MEEDATING THE EFFICACY OF THE
AGENTS.
THATHANK YOU.
I LOOK FORWARD TO QUESTIONS.
>> THANK YOU, JONATHAN.
AND FINALLY, WE HAVE DR. SUZANNE
GARCIA TO PRESENT ON THE
ACCELERATING MEDICINES
PARTNERSHIP FOR SCHIZOPHRENIA.
>> GREAT.
THANK YOU.
GOOD AFTERNOON.
I'M DR. SUZANNE GARCIA.
I'M PLEASED TO PRESENT THIS
CONCEPT FOR ACCELERATING
MEDICINES PARTNERSHIP FOR
SCHIZOPHRENIA.
NEXT SLIDE PLEASE.
THIS IS A LARGE HI HIGH-PROFILE
PUBLIC AND PRIVATE PARTNERSHIP
FROM NIMH AND PUBLIC AND PRIVATE
PARTNERS TO CONDUCT THE MOST
CAMERA HENCEMENT LONGITUDINAL
STUDIES ON INDIVIDUALS AT RISK
FOR SCHIZOPHRENIA.
THE STUDY IS FOCUSED ON
DEVELOPING BIOMARKERS AND
CLINICAL OUTCOME MEASURES YOU
CAN SEE ON THE DIAGRAM ON THE
RIGHT.
SOME OF THE MARKERS INCLUDE
NEUROIMAGING, ASSESSMENTS,
NEUROPHYSIOLOGY, GENETIC
BIOMARKERS, SPEECH AND FACIAL
EXPRESSION AND DIGITAL MEASURES.
COMBINED THE MEASURES WILL
SUPPORTWILLSUPPORT ALGORITHMS.
THE DATA ARE COLLECTED FROM
STUDY PARTICIPANTING AT BASELINE
AND CONTINUING THROUGH 24 MONTHS
AND THE STUDY IS PROJECTED TO BE
COMPLETED IN JUNE OF 2027.
THE OVERARCHING GOAL OF THE
STUDY IS THE DEVELOPMENT OF THE
STOOLS TO IDENTIFY EVERY RISK
FOR SCHIZOPHRENIA THAT CAN BE
USED IN FUTURE CLINICAL TRIALS
TO ASSESS NOVEL INTERVENTIONS.
THIS CONCEPT WOULD SUPPORT THE
SCHIZOPHRENIA DATA PROCESSING
ANALYSIS AND COORDINATION CENTER
THE COMPLETE FINAL DATA
PROCESSING AND ANALYSIS REQUIRED
TO COMPLETE THE 24 MONTH
LONGITUDINAL STUDIES.
NEXT SLIDE PLEASE.
TO DATE, THE STUDY HAS ALREADY
RECRUITED OVER 2,600 STUDY
PARTICIPANTS AND THEY HAVE MET
THEIR RECRUITMENT TARGETS.
ALL PARTICIPANTS HAVE COMPLETED
BASELINE MONTH ONE AND TWO TIME
POINTS.
HOWEVER, CONTINUE COLLECTION OF
THE BIOMARKERS AND CLINICAL
OUTCOME DATA ACROSS THE FULL 24
MONTH IS NEEDED TO COMPLETE THE
FULL DATASET.
BY CONTINUING THE DATA
PROCESSING ANALYSIS THE CENTER
WILL ENSURE CONTINUED DATA WITH
REALTIME QUALITY ASSURANCE AND
QUALITY CONTROL DATA PROCESSING,
CURATION AND SHARING AND
ULTIMATELY COMPLETION OF THE
PRIMARY ANALYSIS OF THIS WHOLE
DATASET.
NEXT SLIDE PLEASE.
THERE ARE FOUR EXPECTED OUTCOMES
FOR SCHIZOPHRENIA.
ONE, WE EXPECT TO SEE HIGH
QUALITY LONGITUDE CAN MULTIMODAL
DATA AND CLINICAL OUTCOMES FROM
A RELATIVELY UNDER STUDIES
POPULATION ACROSS 24 MONTHS.
THTHE CURATED DATA WILL BE SHARD
AS A RESOURCE THROUGH THE NIMH
DATA ARCHIVE OR NDA.
SCHIZOPHRENIA WILL DELIVER ON
THE LARGE PUBLIC AND PRIVATE
ASSESSMENTS FOR THE USE IN
CLINICAL TRIALS OF NOVEL
INTERVENTIONS.
AND FINALLY, THIS INITIATIVE
WILL SIGNIFIC SIGNIFICA SIGNIFIW
THERAPIES FOR THOSE AT RISK FOR
SCHIZOPHRENIA.
THANK YOU FOR YOUR TIME AND
ATTENTION.
>> DR. ANDREA BECKEL-MITCHENER:
GREAT.
THANK YOU, SPACEWALKING SI DR. .
THANK YOU ALL.
NOW, WE WILL OPEN IT UP FOR ANY
OF THE FOUR CONCEPTS PRESENTED.
>> YES?
>> I JUST WANTED TO EXPRESS MY
STRONG SUPPORT FOR THE CONCEPT
CLEARANCE ON OLDER ADULTS LIVING
WITH SERIOUS MENTAL ILLNESS.
I THINK THIS IS A REALLY
IMPORTANT PROBLEM THAT RESONATES
WITH ME JUST BASED ON THE
PATIENTS I SAW IN MY CLINIC LAST
WEEK THAT REALLY SURFER FROM
FRACTURED CARE THAT THEY GET
BECAUSE OF AN EMPHASIS ON
SPECIALIST AND A LACK OF
INTEGRATION.
SO I THINK BETTER INTERVENTIONS
THAT ADDRESS THE SORT OF
MULTIMORBIDITY WE SEE IN THE
PATIENTS WILL BE VERY IMPACTFUL.
>> DR. ANDREA BECKEL-MITCHENER:
THANK YOU.
>> NEXT?
>> YEAH.
I WAS GLAD TO SEE THE CONTINUED
EMPHASIZE ON IMPLEMENTATION
SCIENCE, WHICH IS AN AREA THAT
NIMH HAS BEEN AN ABSOLUTE LEADER
IN THE PAST TWO DECADES AND
REALLY ALLOW OUR DISCOVERY TO
HAVE IMPACT.
I HAVE COMMENTS FOR THE FIRST
THREE CLEARANCES I WILL BE
BRIEF.
DR. SHERYL, WAS HOPING IT COULD
EMPHASIS GOING BEYOND INDIVIDUAL
FACTORS AND RECOGNIZING THAT
TRAINING IS NECESSARY BUT NOT
SUFFICIENT FOR BEHAVIOR CHANGE
AND THINKING ABOUT A MORE
MULTILEVEL LENS.
DR. EVANS, WAS CURIOUS ABOUT
EMPHASIZING HYBRID STUDIES TO
SPEED UP THE PACE AND
EFFECTIVENESS AND
IMPLEMENTATION, AND DR. JONATHAN
SABBAGH IF THERE IS A WA WA %AO
INCORPORATE THAT KIND OF
THINKING NOW INTO THAT CONCEPT
CLEARANCE I WOULD RECOMMEND IT.
THANK YOU.
>> DR. ANDREA BECKEL-MITCHENER:
GREAT, THANK YOU FOR THOSE
COMMENTS.
>> LAURA?
>> THANK YOU.
I ALSO WAS VERY IMPRESSED WITH
THE PROJECT FOR OLDER
INDIVIDUALS TO IMPROVING CARE
FOR THEM.
SO VERY HIGHLY SUPPORT THAT.
AND A QUESTION FOR THE
SCHIZOPHRENIA PROJECT.
WHETHER A STUDY ENDS IN 2027,
RIGHT?
THERE ARE BIOMARKERS AND MANY
THINGS THAT MEANS THAT SUPPORT
IS GOING TO NEED TO GO ON
CONCEIVABLY FOR A VERY LONG
TIME.
SO I WAS CURIOUS ABOUT IT TIME
FRAME, RIGHT OF THE CONTINUED
SUPPORT THAT THIS WAS PROPOSING
AND PROBABLY EVEN LONGER TERM
SUPPORT THAN THAT.
>> SO THE TIMELINE THAT WE HAVE
GIVEN, WILL ALLOW FOR THE
COMPLETE ANALYSIS OF ALL OF THE
DATA POINTS WE WILL BE
RECEIVING.
>> SO THIS IS ESPECIALLY AN
EXTENSION OF AN ONGOING PROGRAM
AND THE TIMELINE, I THINK, IS
ALREADY BEEN BUILT IN SO THIS
WILL WILL BE READY TO GO SHOULDT
BECOME AN AN INITIATIVE, SHOULT
BE ALLOWED TO BE AN INITIATIVE
AT THAT POINT.
IS THAT RIGHT, DR. SUZANNE
GARCIA.
>> THAT IS EXACTLY RIGHT.
THANK YOU, ANDREA.
>> VELMA.
>> HI, , I WOULD LIKE TO OFFER
STRONG SUPPORT FOR JOEL'S
PRESENTATION REGARDING THE
TRAINING OF THE WORKFORCE.
AND WOULD LIKE TO ALSO
EMPHASIZE, I LIKE THE SUGGESTIN
WAS MULTILEVEL TRAINING, BUT
ALSO THINKING OF WAYS TO REALLY
LEVERAGE COMMUNITY HEALTH
WORKERS AS A WAY OF REACHING
WIDER POPULATIONS, PARTICULARLY
RURAL COMMUNITIES, BECAUSE
TELEHEALTH, IT IS A GREAT
PLATFORM FOR DELIVERY, THE MAIL
NOT NECESSARILY BE VIABLE FOR
SOME POPULATIONS.
SO TO REALLY ENCOURAGE
APPLICATIONS I HAVE TO THINK
MUCH MORE BROADLY ABOUT ONE
TRAINING AND THE DELIVERY OF
TRAINING REACHING WIDE
POPULATIONS.
>> THANK YOU.
THANK YOU FOR THAT COMMENT.
>> IGNACE?
>> THANKS SO MUCH.
AND FOR ALL OF THE WORK THAT
FOLKS ARE DOING TO PULL THESE
TOGETHER.
MY COMMENT FOR DOCTOR REGARDING
THE SUICIDE APPLICATION, IS THE
IMPORTANCE OF GETTING OTHER
STAKEHOLDERS LIKE SAMSA
INVOLVED.
I KNOW I HAVE MADE THAT COMMENT
BEFORE.
BUT IN TERMS OF FACILITATING,
WELL, THE -- THE POINTS THAT HE
WAS MAKING AND MOVING FROM THE
RESEARCH TO THE IMPLEMENTATION.
HAVING THAT, THOSE FOLKS AT THE
TABLE.
THEY KNOW A LOT ABOUT THAT KIND
OF THING.
AND THEY MAY BE THERE.
IT WOULD BE GREAT TO HAVE THEM.
I THINK MY MAIN COMMENTS,
THOUGH, ARE FOR DR. SUZANNE
GARCIA -- SORRY?
FOR DR. SUZANNE GARCIA WITH
REGARDS TO THE SCHIZOPHRENIA.
BECAUSE THIS, IT SOUNDS LIKE
MOST OF THE OTHER CONCEPT
CLEARANCES AND THE CONCEPT
CLEARANCES THAT I'M, THAT I'M
ACCUSTOMED TO ARE IN THE CONTEXT
OF RFAs.
AND THAT ARE, THAT ARE GOING TO
BE DRAWING IN PROPOSALS.
THIS, THIS SEEMED LIKE A, A
GROUP THAT, WELL, FIRST OFF, IT
ITIS A GROUP, YOU KNOW, TH THEYT
GREAT FOLKS WORKING THERE.
IT IS IMPORTANT TO KEEP THAT,
THAT GROUP TOGETHER.
I -- I CONCUR.
BUT IT -- MADE ME WONDER WHAT IS
THE NATURE OF THIS CONCEPT
CLEARANCE AND WHAT ARE THE
MECHANISMS THAT NIMH HAS FOR
ALLOCATING FUNDS TO A RESEARCH
CENTER IT WANTS TO SUPPORT IN A
NONCOMPETITIVE MANNER IT SEEMS
SILLY TO MAKE THIS A PUBLISHED
COMPETITIVE RFA.
BUT IT WOULD MAKE SENSE TO HAVE
THE BUDGET SCRUTINIZED AT --
BASED ON WHAT IT IS THAT THOSE
FUNDS ARE GOING TO BE USED FOR,
HOW TO MAKE THE MOST OF THEM.
AND ALSO, WHAT IS THE -- IT IS A
PUBLIC-PRIPUBLIC-PRIVATE PARTNES
THERE ANY EXPECTATION THAT THE
PRIVATE SECTOR IS GOING TO COME
FORWARD AND -- AND -- THEY ARE
CERTAINLY BENEFITING FROM THIS.
HOW, WHAT IS THEIR STAKE IN
THIS?
AND SO THOSE ARE MY COMMENTS
WITH REGARDS TO -- TRYING TO
MOVE THAT FORWARD.
>> EXCELLENT, THANK YOU FOR
THOSE COMMENTS.
YES, WE WILL CONTINUE HAVING THE
PUBLIC-PRIVATE PARTNERSHIP IN
THIS.
THEY WILL CONTINUE FINANCIALLY
HELPING US MOVE THIS FORWARD.
AND THE REASON THAT WE'RE ASKING
FOR THIS CONTINUED SUPPORT ON
THE MECHANISM WAS LARGELY DUE TO
THE FACT THAT THERE WAS MORE
TIME THEN WE EXPECTED THAT WAS
NEEDED TO FINALIZE THIS
PARTNERSHIP.
AND WE'RE HOPING TOKER BE ABLE
TO DOLLAR LIVE ON THE
PUBNICTIATE THAT WE HAVE
RECREATED.
>> SO, THIS IS A NEW MECHANISM?
>> WE DO HAVE A MECHANISM FOR
SINGLE SOURCE AMLUMICATIONS AT
THE NIH.
IT COMES WITH A LOT OF
ADDITIONAL JUSTIFICATIONS.
THAT WE HAVE -- THAT WE ARE
UNDERGOING.
AND WE WILL UNDERGO RIGOROUS
REVIEW FOR.
FROM THE NI NIH, AND OF COURSE,L
APPLICATIONS SUBMITTED WILL
UNDERGO PEER REVIEW.
>> AGAIN, IT IS IMPORTANT TO
NOTE AT THIS STAGE, IT IS
CONCEPT, IT IS STILL IN OUR BEST
INTEREST, AND CONCUR WITH
CONTINUING IN THIS VEIN.
WE HAVE A LOT OF WORK TO DO TO
KNOW HOW THAT SUPPORT MIGHT BE
PROVIDED.
WE TEND NOT TO COMMIT TO ANY
PARTICULAR GRANT MECHANISM OR
FUNDING MECHANISM AT THIS STAGE.
BUT WE ARE STILL VERY INTERESTED
IN CONTINUING THE -- THE
PROJECT, THE -- PROJECT WITH OUR
PRIVATE PARTNERS AS WELL.
WITH FMIH.
>> THANK YOU.
>> NOW, WE'RE AT THE PUBLIC
COMMENT TIME.
>> DR. ANDREA BECKEL-MITCHENER:
SO WE HAVE STAYED EXACTLY ON
TIME.
I'M ABSOLUTELY AMAZED.
THIS WOULD BE THE POINT IN OUR
MEETING WHERE WE WOULD ASK FOR
PUBLIC COMMENTS.
WE HAVE NOT RECEIVED ANY WRITTEN
COMMENTS PRIOR TO THE MEETING
THERE FORE WE HAVE NO PUBLIC
COMMONITARY FOR THE MEETING.
OUR PUBLIC IS WELCOME TO SUBMIT
COMMENTS THROUGH THE NORMAL
AVENUES THAT ARE AVAILABLE TO
US, YOU CAN SEE THAT ON THE
WEBSITE FOR ANYONE LISTENING OUT
THERE.
SO THANK YOU ALL.
THANK YOU FOR JOINING US FOR THE
OPEN SESSION.
WE APPRECIATE YOUR INPUT VERY
MUCH.
WE WILL ADJOURN THIS OPEN POLICY
SESSION.
FOR COUNCILMEMBERS OUR CLOSED
GRANT REVIEW SESSION, THE LAST
ONE OF THE DAY WILL CONVENE AT
1:15 P.M. EASTERN TIME, YOU CAN
AGAIN REMAIN ON THE TEAMS
MEETING YOU ARE ON NOW.
WE WILL SEE YOU JUST BEFORE 1:1.
THANK YOU ALL.
[ EVENT CONCLUDED ]